Ki Hong Ahn

Board of Directors, CEO of HLB Therapeutics

Ki Hong Ahn is the CEO of HLB Therapeutics, a South Korean KOSDAQ-listed pharmaceutical company specializing in new drug development. Before becoming the CEO of HLB Therapeutics, he served as a Vice President of HLB, a listed company, and as Vice President of HLB Life Science. Mr. Ahn began his career as a banker at the national policy bank, Korea Long Term Credit Bank. He then worked in financial executive roles for decades, including as the Head of Financial Strategy at E-Land Group and CFO of Yakjin Trading. He earned a bachelor’s degree from Hankuk University of Foreign Studies in Korea and a master’s from Waseda University in Japan.